CTHRC1 Antibody (1G12): sc-293270

CTHRC1 Antibody (1G12) is a mouse monoclonal IgG2a kappa light chain antibody that detects CTHRC1 protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Anti-CTHRC1 antibody (1G12) is available as a non-conjugated format. CTHRC1, or collagen triple helix repeat containing 1, is a 243 amino acid secreted protein primarily located in the extracellular matrix and features a collagen-like domain, which is crucial for structural role in tissue integrity and repair. CTHRC1 is expressed in two alternatively spliced isoforms, with one isoform notably found in calcified atherosclerotic plaques and chondrocyte-like cells. CTHRC1 functions as a negative regulator of collagen matrix deposition, which is vital in maintaining the balance of extracellular matrix components and preventing excessive fibrosis. CTHRC1 is implicated in the stabilization of ligand-receptor interactions within the Wnt signaling pathway, a critical pathway involved in cell proliferation and differentiation. CTHRC1 is observed in various cancers, including melanoma and breast carcinoma, where CTHRC1 may facilitate cancer cell migration and contribute to tissue invasion and metastasis. The gene encoding CTHRC1 is located on human chromosome 8, a region that spans nearly 146 million base pairs and contains over 800 genes, many of which are associated with diverse diseases and malignancies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CTHRC1 Antibody (1G12) References:

1. Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration.  |  Pyagay, P., et al. 2005. Circ Res. 96: 261-8. PMID: 15618538
2. Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers.  |  Tang, L., et al. 2006. Clin Cancer Res. 12: 3716-22. PMID: 16778098
3. Cthrc1 is a novel inhibitor of transforming growth factor-beta signaling and neointimal lesion formation.  |  LeClair, RJ., et al. 2007. Circ Res. 100: 826-33. PMID: 17322174
4. The role of collagen triple helix repeat containing 1 in injured arteries, collagen expression, and transforming growth factor beta signaling.  |  LeClair, R. and Lindner, V. 2007. Trends Cardiovasc Med. 17: 202-5. PMID: 17662915
5. Intracellular localization of Cthrc1 characterizes differentiated smooth muscle.  |  Leclair, RJ., et al. 2008. Arterioscler Thromb Vasc Biol. 28: 1332-8. PMID: 18467647
6. Leading Wnt down a PCP path: Cthrc1 acts as a coreceptor in the Wnt-PCP pathway.  |  Kelley, MW. 2008. Dev Cell. 15: 7-8. PMID: 18606135
7. Cthrc1 selectively activates the planar cell polarity pathway of Wnt signaling by stabilizing the Wnt-receptor complex.  |  Yamamoto, S., et al. 2008. Dev Cell. 15: 23-36. PMID: 18606138
8. Autocrine CTHRC1 activates hepatic stellate cells and promotes liver fibrosis by activating TGF-β signaling.  |  Li, J., et al. 2019. EBioMedicine. 40: 43-55. PMID: 30639416
9. Single-Cell RNA Sequencing Analysis Reveals a Crucial Role for CTHRC1 (Collagen Triple Helix Repeat Containing 1) Cardiac Fibroblasts After Myocardial Infarction.  |  Ruiz-Villalba, A., et al. 2020. Circulation. 142: 1831-1847. PMID: 32972203
10. The molecular mechanisms of CTHRC1 in gastric cancer by integrating TCGA, GEO and GSA datasets.  |  Zhao, L., et al. 2022. Front Genet. 13: 900124. PMID: 35928443
11. CTHRC1+ fibroblasts are stimulated by macrophage-secreted SPP1 to induce excessive collagen deposition in keloids.  |  Liu, J., et al. 2022. Clin Transl Med. 12: e1115. PMID: 36480415
12. CTHRC1: An Emerging Hallmark of Pathogenic Fibroblasts in Lung Fibrosis.  |  Mukhatayev, Z., et al. 2024. Cells. 13: PMID: 38891078

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CTHRC1 Antibody (1G12) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-CTHRC1 Antibody (1G12) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CTHRC1 Antibody (1G12) Specifications

Alternate Product Name: CTHRC1

Product Clone Name: 1G12

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 32-141

Epitope Target: CTHRC1

Epitope Species: human

Product Reactivity/Detection: CTHRC1

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 100 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for CTHRC1 Antibody (1G12): N/A